Literature DB >> 15175812

Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome.

Mathieu R Nendaz1, Patrick Bandelier, Drahomir Aujesky, Jacques Cornuz, Pierre-Marie Roy, Henri Bounameaux, Arnaud Perrier.   

Abstract

A clinical predictive model that accurately identifies patients with pulmonary embolism who are at low risk of adverse medical outcomes may be useful for management decisions, such as outpatient treatment. We aimed to externally validate a previously derived prognostic score identifying emergency ward patients with acute pulmonary embolism at low risk of 3-month complications. One hundred and ninety-nine consecutive patients with proven pulmonary embolism were included from the emergency centres of three teaching and general hospitals. Adverse outcomes, such as death, major bleed, or recurrent venous thromboembolism, were recorded during a 3-month follow-up. We retrospectively computed the prognostic score for each patient and determined its predictive accuracy at different threshold values. The overall 3-month risk of adverse event after the diagnosis of pulmonary embolism was 9.5%. At a threshold of 2 points, eight patients with scores at or below the cut-off (5%; 95% CI 2.6-9.6) and 11 patients with scores above this cut-off (27.5%; 95% CI 16.1-42.8) presented a complication. The negative predictive value for an adverse out-come was 95.0% (95% CI 90.4-97.4). The receiver operating characteristic curve derived from the score distribution had an area of 0.77 (95% CI 0.65-0.89). This compared favourably with the characteristics of the derivation study. We conclude that the Geneva risk score has an acceptable predictive accuracy to identify patients with pulmonary embolism at low risk for 3-month adverse outcomes. Whether this score remains accurate and useful in clinical practice should be determined in a prospective multicentre validation study.

Entities:  

Mesh:

Year:  2004        PMID: 15175812     DOI: 10.1160/TH04-01-0034

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Anticoagulation in the management of venous thromboembolism in the cancer patient.

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

2.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  Identification of patients with low-risk pulmonary embolism suitable for outpatient treatment using the pulmonary embolism severity index (PESI).

Authors:  A McCabe; T Hassan; M Doyle; B McCann
Journal:  Ir J Med Sci       Date:  2012-11-28       Impact factor: 1.568

4.  Outcomes considered most important by emergency physicians when determining disposition of patients with pulmonary embolism.

Authors:  Christopher Kabrhel; Weston Sacco; Shan Liu; Praveen Hariharan
Journal:  Int J Emerg Med       Date:  2010-10-19

5.  The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism.

Authors:  Won-Ho Choi; Sung Uk Kwon; Yoon Jung Jwa; Jung A Kim; Yun-Ho Choi; Je Ho Chang; Hoon Jung; Joon Hyung Doh; June Namgung; Sung Yun Lee; Won Ro Lee
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

Review 6.  New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants.

Authors:  Alessandro Squizzato
Journal:  Scientifica (Cairo)       Date:  2012-12-17

Review 7.  Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis.

Authors:  Antoine Elias; Susan Mallett; Marie Daoud-Elias; Jean-Noël Poggi; Mike Clarke
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.